MX2020006459A - Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar. - Google Patents

Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar.

Info

Publication number
MX2020006459A
MX2020006459A MX2020006459A MX2020006459A MX2020006459A MX 2020006459 A MX2020006459 A MX 2020006459A MX 2020006459 A MX2020006459 A MX 2020006459A MX 2020006459 A MX2020006459 A MX 2020006459A MX 2020006459 A MX2020006459 A MX 2020006459A
Authority
MX
Mexico
Prior art keywords
fused ring
ring compounds
diaryl substituted
c5ar inhibitors
c5ar
Prior art date
Application number
MX2020006459A
Other languages
English (en)
Inventor
Christopher W Lange
Venkat Reddy Mali
Sreenivas Punna
Yibin Zeng
Pingchen Fan
Viengkham Malathong
Hiroko Tanaka
Penglie Zhang
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of MX2020006459A publication Critical patent/MX2020006459A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

La presente exposición proporciona, inter alia, los compuestos de la fórmula (I) Ver formula (I) o sales farmacéuticamente aceptables de los mismos que son moduladores del receptor de C5a. También se proporcionan composiciones farmacéuticas y métodos de uso que incluyen el tratamiento de enfermedades o trastornos que implican la activación patológica de C5a y aplicaciones no farmacéuticas.
MX2020006459A 2017-12-22 2018-12-20 Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar. MX2020006459A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762609834P 2017-12-22 2017-12-22
PCT/US2018/066667 WO2019126424A1 (en) 2017-12-22 2018-12-20 DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS

Publications (1)

Publication Number Publication Date
MX2020006459A true MX2020006459A (es) 2020-11-06

Family

ID=66949183

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006459A MX2020006459A (es) 2017-12-22 2018-12-20 Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar.

Country Status (14)

Country Link
US (3) US10828285B2 (es)
EP (1) EP3728203B1 (es)
JP (1) JP7254082B2 (es)
KR (1) KR20200109316A (es)
CN (1) CN111788185A (es)
AU (1) AU2018388655C1 (es)
BR (1) BR112020012270A2 (es)
CA (1) CA3085946A1 (es)
IL (1) IL275500B2 (es)
MA (1) MA51331A (es)
MX (1) MX2020006459A (es)
SG (1) SG11202005791QA (es)
TW (1) TWI789470B (es)
WO (1) WO2019126424A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018222598A1 (en) 2017-05-31 2018-12-06 Chemocentryx, Inc. 6-5 FUSED RINGS AS C5a INHIBITORS
WO2018222601A1 (en) 2017-05-31 2018-12-06 Chemocentryx, Inc. 5-5 FUSED RINGS AS C5a INHIBITORS
CN111406051A (zh) 2017-09-03 2020-07-10 安吉昂生物医药公司 作为rho相关卷曲螺旋激酶(rock)抑制剂的乙烯基杂环
EP3728203B1 (en) 2017-12-22 2024-03-13 ChemoCentryx, Inc. DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS
CN111788184B (zh) * 2017-12-22 2023-12-22 凯莫森特里克斯股份有限公司 用作C5aR抑制剂的二芳基取代的5,5-稠合环化合物
EP3773563A4 (en) * 2018-04-02 2021-12-29 ChemoCentryx, Inc. Prodrugs of fused-bicyclic c5ar antagonists
CA3157394A1 (en) 2019-12-19 2021-06-24 Helena ERIKSSON Compounds for treatment of eye diseases associated with excessive vascularisation
TW202142538A (zh) 2020-02-07 2021-11-16 美商迦舒布魯姆生物有限公司 雜環ｇｌｐ－１促效劑
EP3868368A1 (en) * 2020-02-21 2021-08-25 Dompe' Farmaceutici S.P.A. Cxcl8 (interleukin-8) activity inhibitor and corticosteroid combination and pharmaceutical composition and use thereof
CA3192880A1 (en) 2020-10-28 2022-05-05 Chemocentryx, Inc. Methods of treating hidradenitis suppurativa
CN113143920B (zh) * 2021-05-25 2023-04-25 湖北工业大学 Ponesimod化合物在制备抗EV71病毒药物中的应用
CN116983264B (zh) * 2023-09-28 2023-12-22 中国农业科学院农产品加工研究所 一种二氢***二酚二苯甲酸酯的包埋体系及其制备方法和应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1268002A (en) 1917-09-12 1918-05-28 William M Goodwin Measuring instrument.
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
DK27383A (da) * 1982-02-17 1983-08-18 Lepetit Spa Fremgangsmaade til fremstilling af pyrazol(4,3-c)pyridiner
NZ524475A (en) * 2000-08-10 2004-11-26 Pharmacia Italia S Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
DE60039921D1 (de) 2000-09-29 2008-09-25 Neurogen Corp Hochaffine kleinmolekülige c5a-rezeptor-modulatoren
SE524438C2 (sv) 2000-10-05 2004-08-10 Magnus Georg Goertz Fjärrstyrt dörrelaterat låsarrangemang, första och andra datorpogramprodukt, bärande medium och ett datorlösbart medium
WO2002088122A1 (fr) 2001-04-26 2002-11-07 Ajinomoto Co., Inc. Composes heterocycliques
DE10231783A1 (de) 2001-07-19 2003-03-20 Luk Lamellen & Kupplungsbau System zum Ansteuern einer Komponente eines Getriebes eines Fahrzeuges
ITMI20012025A1 (it) 2001-09-28 2003-03-28 Dompe Spa Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono
EP1487798A4 (en) 2002-03-28 2005-07-13 Neurogen Corp Substituted tetrahydroisoquinolines as C5A receptor modulators
EP1487796A4 (en) 2002-03-28 2005-11-16 Neurogen Corp SUBSTITUTED BIARYLAMIDES AS MODULATORS OF THE C5A RECEPTOR
JP2005530719A (ja) 2002-03-29 2005-10-13 ニューロジェン コーポレーション 病原性炎症要素を有する状態の治療のための組み合わせ療法
AU2003265395A1 (en) 2002-08-14 2004-03-03 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
AU2003265625A1 (en) 2002-08-21 2004-03-11 Neurogen Corporation Amino methyl imidazoles as c5a receptor modulators
WO2004043925A2 (en) 2002-11-08 2004-05-27 Neurogen Corporation 3-substituted-6-aryl pyridined as ligands of c5a receptors
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US20040214856A1 (en) 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
AU2003902354A0 (en) 2003-05-15 2003-05-29 Harkin, Denis W. Treatment of haemorrhagic shock
US20060154917A1 (en) 2003-07-03 2006-07-13 Neurogen Corporation Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators
WO2006042102A2 (en) 2004-10-05 2006-04-20 Neurogen Corporation Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
UA95247C2 (ru) * 2005-08-04 2011-07-25 Янссен Фармацевтика Н.В. Пиримидиновые соединения как модуляторы рецептора серотонина
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
WO2007051062A2 (en) 2005-10-28 2007-05-03 Chemocentryx, Inc. Substituted dihydropyridines and methods of use
US20080119457A1 (en) * 2006-08-24 2008-05-22 Serenex, Inc. Benzene, Pyridine, and Pyridazine Derivatives
PE20110063A1 (es) 2008-06-20 2011-02-16 Genentech Inc DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK
US20110275639A1 (en) 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
MA32975B1 (fr) 2008-12-22 2012-01-02 Chemocentryx Inc Antagonistes de c5ar
SI2585064T1 (sl) 2010-06-24 2017-08-31 Chemocentryx, Inc. Antagonisti C5AR
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
EP2885304B8 (en) 2012-08-16 2016-12-07 Janssen Pharmaceutica NV Pyrrolopyrazoles as n-type calcium channel blockers
CN103421006B (zh) 2013-08-18 2016-06-22 上海师范大学 2,3,5,7-四取代二氢吡唑并六氢吡啶衍生物及其制备方法和应用
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
CN109310686B (zh) 2016-04-04 2022-06-21 凯莫森特里克斯股份有限公司 可溶性C5aR拮抗剂
WO2018222598A1 (en) 2017-05-31 2018-12-06 Chemocentryx, Inc. 6-5 FUSED RINGS AS C5a INHIBITORS
WO2018222601A1 (en) 2017-05-31 2018-12-06 Chemocentryx, Inc. 5-5 FUSED RINGS AS C5a INHIBITORS
US10589871B2 (en) 2017-09-25 2020-03-17 Hamilton Sundstrand Corporation Prognostic health monitoring and jam detection for use with an aircraft
CN111788184B (zh) * 2017-12-22 2023-12-22 凯莫森特里克斯股份有限公司 用作C5aR抑制剂的二芳基取代的5,5-稠合环化合物
EP3728203B1 (en) 2017-12-22 2024-03-13 ChemoCentryx, Inc. DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS
EP3773563A4 (en) * 2018-04-02 2021-12-29 ChemoCentryx, Inc. Prodrugs of fused-bicyclic c5ar antagonists

Also Published As

Publication number Publication date
EP3728203A4 (en) 2021-06-16
CN111788185A (zh) 2020-10-16
US10828285B2 (en) 2020-11-10
AU2018388655C1 (en) 2023-03-23
TW201927782A (zh) 2019-07-16
SG11202005791QA (en) 2020-07-29
TWI789470B (zh) 2023-01-11
RU2020124093A (ru) 2022-01-25
US20210106568A1 (en) 2021-04-15
US20230115912A1 (en) 2023-04-13
AU2018388655A1 (en) 2020-07-09
IL275500A (en) 2020-08-31
JP7254082B2 (ja) 2023-04-07
CA3085946A1 (en) 2019-06-27
BR112020012270A2 (pt) 2020-11-24
JP2021506893A (ja) 2021-02-22
IL275500B2 (en) 2023-05-01
WO2019126424A1 (en) 2019-06-27
IL275500B1 (en) 2023-01-01
US20190192491A1 (en) 2019-06-27
AU2018388655B2 (en) 2022-11-24
EP3728203A1 (en) 2020-10-28
KR20200109316A (ko) 2020-09-22
MA51331A (fr) 2020-10-28
US11478460B2 (en) 2022-10-25
EP3728203B1 (en) 2024-03-13

Similar Documents

Publication Publication Date Title
NZ765590A (en) Diaryl substituted 5,5-fused ring compounds as c5ar inhibitors
MX2020006459A (es) Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar.
ZA201907746B (en) 6-5 fused rings as c5a inhibitors
MX2019014292A (es) Anillos 5-5 fusionados como inhibidores c5a.
MX2020010390A (es) Profarmacos de antagonistas de c5ar biciclicos fusionados.
NZ768368A (en) Modulators of cystic fibrosis transmembrane conductance regulator
CR20200553A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
PH12017500810A1 (en) Substituted 2,4 diamino-quinoline as new anticancer agents
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
PH12019500568A1 (en) Dopamine-b-hydroxylase inhibitors
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
MX2021003945A (es) Compuestos de indolinona para uso como inhibidores de map4k1.
PH12018500432A1 (en) Heteroaryl compounds and their use as therapeutic drugs
WO2018183631A8 (en) Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
MX2018014185A (es) Combinacion de antagonistas puros del receptor 5 ht6 con inhibidores de la acetilcolinesterasa.
PH12017501668A1 (en) Bace1 inhibitors
PH12020500542A1 (en) Dopamine-b-hydroxylase inhibitors
PH12021550258A1 (en) Cdk8/19 inhibitors
ZA202100955B (en) Thrombin inhibitors, formulations, and uses thereof
PH12020500233A1 (en) Adamantylmethylamine derivative and use thereof as pharmaceutical
JOP20200104A1 (ar) مركبات مثبطة لـ btk
MX2016016061A (es) 2,2,2-trifluoroetil-tiadiazinas.
MX2021003204A (es) Compuesto que contiene oxadiazol y composicion farmaceutica que contiene el mismo.